NaviFUS (ROCO:6872) ROCE % : -18.90% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NaviFUS ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NaviFUS's annualized ROCE % for the quarter that ended in Jun. 2024 was -18.90%.

NaviFUS ROCE % Historical Data

The historical data trend for NaviFUS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NaviFUS ROCE % Chart

NaviFUS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-23.35

-21.62

-18.17

-11.90

-14.32

NaviFUS Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial						-9.58	-14.25	-7.09	-20.90	-18.90

NaviFUS ROCE % Calculation

NaviFUS's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-69.136	/	( ( (524.067 - 21.192)	+	(490.535 - 27.564) )	/ 2 )
	=	-69.136	/	( (502.875	+	462.971)	/ 2 )
	=	-69.136	/	482.923
	=	-14.32 %

NaviFUS's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-97.138	/	( ( (490.535 - 27.564)	+	(610.903 - 45.816) )	/ 2 )
	=	-97.138	/	( ( 462.971	+	565.087 )	/ 2 )
	=	-97.138	/	514.029
	=	-18.90 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

NaviFUS (ROCO:6872) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NaviFUS ROCE % Related Terms

Thank you for viewing the detailed overview of NaviFUS's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

NaviFUS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.246, Sec 3, Chengde Road, 12th Floor, Datong District, Taipei City, TWN, 103

Website

https://www.navifus.com

NaviFUS Corp is a Biotech company providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Its product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for better treatment outcomes. Its vision is to cater to CNS disease patients locally and globally by bringing therapeutic ultrasound technology to clinical use.

NaviFUS Headlines

No Headlines